Foreign Pharma Giants Recalibrate DEI Strategies Amid Regulatory Shifts

Roche and Novartis join a growing list of companies rethinking diversity, equity, and inclusion (DEI) programs as political and legal landscapes evolve.

Pharma Companies Adjust Their DEI Approaches

DEI programs are undergoing significant changes in the pharmaceutical industry, with global leaders Roche and Novartis taking steps to reshape their diversity initiatives.

• Roche has announced that its chief diversity offices in both the U.S. and its Swiss headquarters will now prioritize “inclusion and belonging” rather than diversity targets. The company is also eliminating global workforce diversity targets in favor of fostering a more general inclusive environment.
• Novartis has confirmed that it will end the use of diverse hiring panels in the U.S., a move aligning with broader corporate trends away from structured DEI policies.

Political and Regulatory Pressures

The shift in DEI strategies follows increased political scrutiny, including criticism from former U.S. President Donald Trump. Roche acknowledged in a statement that it is adjusting its programs to remain compliant with recent U.S. executive orders on DEI.

Other pharmaceutical giants have also made quiet modifications:

• Pfizer has rebranded its DEI webpage to emphasize "Merit-Based Diversity", moving away from previous language.
• Bristol Myers Squibb, Johnson & Johnson, and Biogen have removed DEI references from annual reports.

Read more news of this category here.

Corporate America Follows Suit

The pharma industry is not alone in reassessing its DEI commitments. Major brands including Target and Disney have altered their diversity programs, while Apple and Costco have maintained their DEI efforts despite external pressures.

This trend suggests a broader corporate recalibration, as companies weigh legal risks, political considerations, and evolving workforce expectations.

🔗 Visit our marketplace here.